LOTTE BIOLOGICS and AbTis Sign MOU to Co-Develop Next-Generation Technology for ADC Toolbox

■  Joint development of ADC technology to enhance flexibility and expand CDMO services
■  Strengthening one-stop ADC platform service from development to manufacturing

▲ [Photo] LOTTE BIOLOGICS and AbTis Sign MOU Ceremony

LOTTE BIOLOGICS (CEO James Park) announced that it has signed a Memorandum of Understanding (MOU) with AbTis (CEO and President Taedong Han), a company under Dong-A Socio Group specializing in antibody-drug conjugates (ADCs), to collaborate on the development of next-generation ADC technology as part of LOTTE BIOLOGICS’ ADC toolbox.

Through this agreement, the two companies plan to jointly promote their services by combining AbTis’s AbClick® technology with LOTTE BIOLOGICS’ conjugation manufacturing capabilities at its Syracuse Bio Campus in New York. The partnership aims to broaden the scope of LOTTE BIOLOGICS’ ADC toolbox and enhance competitiveness in the global ADC new drug development and contract development and manufacturing organization (CDMO) markets.

As part of the collaboration, a feasibility assessment of the AbClick® platform is also planned at LOTTE BIOLOGICS’ Syracuse facility to explore its potential integration into the ADC manufacturing workflow.

Currently, LOTTE BIOLOGICS offers a flexible ADC toolbox service that enables clients to choose from a range of conjugation technologies, including its proprietary SoluFlex Link™ platform. The company also provides end-to-end CDMO services, from antibody development and clinical supply to large-scale commercial manufacturing.

AbTis holds proprietary AbClick® linker technology, a third-generation platform that allows site-specific drug conjugation to the Fc domain of antibodies without requiring engineered mutants. This site-selective conjugation ensures high product homogeneity and a consistent drug-to-antibody ratio (DAR), resulting in improved quality and efficacy.

James Park, CEO of LOTTE BIOLOGICS, commented,
“This MOU will serve as a catalyst to maximize the technological strengths of both companies. We aim to contribute not only to the development of differentiated ADC therapies but also to improving the quality of life for patients around the world.”

Taedong Han, CEO and President of AbTis, added,
“We are excited to partner with LOTTE BIOLOGICS, a company with deep expertise in antibody production and growing presence in the ADC field. By combining our respective technologies, we expect to significantly strengthen our global competitiveness.”